BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 23, 2015
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg2/20 cls
Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)Cantor FitzgeraldIrina Rivkind KofflerPrice targetBuy61%$33.68
William BlairTim LugoPrice targetOutperform
Koffler raised her target to $37 from $30 after Eagle granted Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) exclusive rights to commercialize EP-3102 in the U.S. This month, Eagle submitted an NDA to FDA for the ready-to-dilute formulation of alkylating agent bendamustine to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin's lymphoma (NHL). If approved, Koffler expects EP-3102 to launch in 2H15 or early 2016 and to replace Teva's existing liquid product, Treanda bendamustine. Eagle will receive $30M in cash up front and is...

Read the full 621 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >